PRNewswire (Fri, 24-Jan 5:20 PM ET)
Business Wire (Fri, 10-Jan 5:44 PM ET)
Humana Inc. to Release Fourth Quarter 2024 Results on February 11, 2025
Business Wire (Thu, 9-Jan 4:30 PM ET)
If HUM Price Stays Between $265 to $275 Range This Iron Condor Will Yield 91%
Market Chameleon (Wed, 8-Jan 3:48 PM ET)
Humana Earns Equality 100 Award in Human Rights Campaign Foundation's 2025 Corporate Equality Index
Business Wire (Tue, 7-Jan 12:26 PM ET)
Humana Names Japan Mehta as Chief Information Officer
Business Wire (Fri, 20-Dec 8:00 AM ET)
Business Wire (Thu, 19-Dec 10:15 AM ET)
Business Wire (Thu, 5-Dec 11:09 AM ET)
Humana Announces CFO Transition
Business Wire (Tue, 3-Dec 8:05 AM ET)
PRNewswire (Mon, 18-Nov 9:12 PM ET)
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Humana trades on the NYSE stock market under the symbol HUM.
As of February 4, 2025, HUM stock price climbed to $295.53 with 1,462,347 million shares trading.
HUM has a beta of 0.40, meaning it tends to be less sensitive to market movements. HUM has a correlation of 0.01 to the broad based SPY ETF.
HUM has a market cap of $35.61 billion. This is considered a Large Cap stock.
Last quarter Humana reported $29 billion in Revenue and $4.16 earnings per share. This beat revenue expectation by $630 million and exceeded earnings estimates by $.76.
In the last 3 years, HUM traded as high as $571.30 and as low as $213.31.
The top ETF exchange traded funds that HUM belongs to (by Net Assets): VTI, VOO, SPY, IVV, VO.
HUM has underperformed the market in the last year with a return of -21.1%, while SPY returned +23.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in HUM shares. However, HUM has outperformed the market in the last 3 month and 2 week periods, returning +13.7% and +4.6%, while SPY returned +5.7% and +0.7%, respectively. This indicates HUM has been having a stronger performance recently.
HUM support price is $285.62 and resistance is $300.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HUM shares will trade within this expected range on the day.